Wei Ying Jen, BM BCh, FRCPath
Department of Leukemia, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
Education & Training
Degree-Granting Education
| 2019 | Royal College of Pathologists, GB, Fellowship of the Royal College of Pathologists |
| 2015 | National University of Singapore, Singapore, SG, Internal Medicine, Master of Medicine |
| 2015 | University of Oxford, Oxford, Oxfordshire, GB, Master of Arts |
| 2015 | Royal College of Physicians, GB, Membership of the Royal College of Physicians |
| 2012 | University of Oxford, Oxford, Oxfordshire, GB, Bachelor of Medicine and Bachelor of Surgery |
| 2009 | University of Oxford, Oxford, Oxfordshire, GB, Medical Sciences, Bachelor of Arts |
Postgraduate Training
| 2023-2024 | Fellow, Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2016-2019 | Senior Resident, Haematology, National University Cancer Institute, Singapore, Singapore, Singapore |
| 2013-2016 | Resident, Internal Medicine, National University Hospital, Singapore, Singapore |
| 2013-2013 | House Officer, General Medicine, National University Hospital, Singapore, Singapore |
| 2013-2013 | House Officer, KK Women's & Children's Hospital, Singapore, Singapore |
| 2012-2013 | House Officer, Singapore General Hospital, Singapore, Singapore |
Experience & Service
Academic Appointments
Adjunct Assistant Professor, Department of Medicine, National University of Singapore Yong Loo Lin School of Medicine, Singapore, Singapore, 2023 - 2024
Senior Lecturer, Department of Medicine, National University of Singapore Yong Loo Lin School of Medicine, Singapore, Singapore, 2019 - 2023
Clinical Lecturer, Department of Medicine, National University of Singapore Yong Loo Lin School of Medicine, Singapore, Singapore, 2017 - 2019
Administrative Appointments/Responsibilities
Undergraduate Division Director, Department of Medicine, National University of Singapore Yong Loo Lin School of Medicine, Singapore, Singapore, 2022 - 2024
System Block Lead, Department of Medicine, National University of Singapore Yong Loo Lin School of Medicine, Singapore, Singapore, 2021 - 2023
Institutional Committee Activities
Key Opinion Leader, Singapore Translational Cancer Consortium, 2022 - Present
Member, Asia-Pacific Leukaemia Consortium, 2022 - Present
Member, Telemedicine Committee, 2020 - 2024
Member, NUHS App Workgroup, 2020 - 2024
Member, NCIS Right Siting Workgroup, 2019 - 2024
Member, Resident's Research Committee, 2018 - 2019
Member, NCIS Annual Research Meeting Scientific Committee, 2018 - 2020
Chairperson, Institutional Review Board, 2017 - 2019
Member, Residents' Welfare Committee, 2015 - 2016
Honors & Awards
| 2024 | EHA Educational Travel Grant, European Hematology Association |
| 2024 | Conquer Cancer – Eisai Inc. Endowed Merit Award, American Society of Clinical Oncology |
| 2023 | NCIS SHINE Incredible Care Award, Nominated by peers, allied health and supervisors to recognise staff who have contributed significantly to the institution and positively influenced their teams |
| 2022 | The Public Administration Medal (Bronze) (COVID-19), Prime Minister's Office, Singapore |
| 2022 | NCIS SHINE Incredible People Award, National University Cancer Institute, Singapore |
| 2020 | Quality Improvement Project Merit Award, National University Hospital |
| 2020 | Best Trainee Award, Chapter of Haematologists, College of Physicians, Academy of Medicine, Singapore |
| 2017 | Best Senior Resident Tutor Award, University Medicine Cluster, National University Hospital |
| 2016 | Junior Doctor Teaching Award, National University of Singapore Yong Loo Lin School of Medicine |
| 2014 | Best Poster Award, World Congress of Internal Medicine |
| 2012 | St Catherine's College Book Prize, St Catherine's College, University of Oxford |
| 2011 | Wellcome Trust Student Elective Prize, Wellcome Trust |
| 2010 | Glaxo Scholarship, St Catherine's College, University of Oxford |
| 2010 | Light Senior Scholarship, St Catherine's College, University of Oxford |
| 2009 | St Catherine's College Book Prize, St Catherine's College, University of Oxford |
| 2009 | Gibbs Prize, Pre-Clinical Faculty Office, University of Oxford |
| 2008 | College Exhibition, St Catherine's College, University of Oxford |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Jen, WY, Marvin-Peek, J, Kantarjian, HM, Alvarado, Y, Borthakur, G, Jabbour, EJ, Wierda, WG, Kadia, TM, Daver, N, DiNardo, C, Short, NJ, Jain, N, Ferrajoli, A, Kornblau, SM, Yilmaz, M, Ohanian, M, McCue, D, Burger, JA, Hammond, DE, Patel, K, Issa, GC, Pemmaraju, N, Sasaki, K, Maiti, A, Abbas, HA, Chien, KS, Takahashi, K, Haddad, FG, Bose, P, Masarova, L, Montalban Bravo, G, Swaminathan, M, Brandt, M, Pierce, S, Garcia-Manero, G, Ravandi, F. Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia. Cancer 131(1), 2025. e-Pub 2025. PMID: 39584789.
- Sahib, NM, Mohamed, JS, Rashid, MA, Jayalakshmi, Lin, YC, Chee, YL, Fan, BE, De Mel, S, Ooi, M, Jen, WY, Chow, EH. A Combinatorial Functional Precision Medicine Platform for Rapid Therapeutic Response Prediction in AML. Cancer medicine 13(22), 2024. e-Pub 2024. PMID: 39560206.
- Marvin-Peek J, Jen WY, Ravandi F. Long-term results of the sequential combination of cladribine and rituximab in Hairy cell leukemia. Leuk Lymphoma. e-Pub 2024. PMID: 38749022.
- Jen WY, Sasaki K, Loghavi S, Wang SA, Qiao W, Borthakur G, Ravandi F, Kadia TM, Issa GC, Short NJ, Yilmaz M, Daver NG, DiNardo CD. Characteristics and outcomes of acute myeloid leukaemia patients with baseline CD7 expression. Br J Haematol. e-Pub 2024. PMID: 38603594.
- Song Y, Lee SY, Chee Y, Jen WY. Hypertensive Emergency with Thrombotic Microangiopathy or TTP? A Case Series and Literature Review. J Clin Med 13(7):1880, 2024. e-Pub 2024. PMID: 38610645.
- Jen WY, Sasaki K, Rausch CR, DiNardo CD, Kadia TM, Yilmaz M, Borthakur G, Alvarado Y, McCue D, McCue D, Kantarjian HM, Ravandi F. Acute kidney injury in acute promyelocytic leukemia: a possible adverse effect of high dose arsenic trioxide in obese patients. Leuk Lymphoma 65(3):378-382, 2024. e-Pub 2024. PMID: 38054837.
- Tan CJ, Yun Tan MS, Nagarajan C, Chng WJ, Chee YL, Ooi M, Kiat Ng LC, Chen Y, Yin Yoong JS, Wong XY, Jen WY. Factors Affecting Patient and Caregiver Preferences for Treatment of Myeloma and Indolent Lymphoma. JCO Oncol Pract 19(12):1168-1178, 2023. e-Pub 2023. PMID: 37844267.
- Lee SY, Y Teo WZ, Lim CXQ, Lee CT, Jen WY, Mel SD, Yap ES, Chee YL. Venous thromboembolism in an Asian COVID-19 cohort across 3 infection waves—a retrospective observational study. Res Pract Thromb Haemost 7(7):102218, 2023. e-Pub 2023. PMID: 38077823.
- Jen WY, Chan ZY, Lee YM, Ng N, Tan B, Teo C, Wong YP, Chee CE, Chee YL. Reducing Chemotherapy Waiting Times in the Ambulatory Setting of a Tertiary Cancer Centre Using a Design Thinking Approach. Cancers (Basel) 15(18):4625, 2023. e-Pub 2023. PMID: 37760594.
- Guo M, Man Chan TH, Zhou Q, An O, Li Y, Song Y, Tan ZH, En Ng VH, Peramangalam PS, Tan ZQ, Cao X, Iwanaga E, Matsuoka M, M Ooi MG, Jen WY, Koh LP, Chan E, Tan LK, Goh Y, Wang W, H Koh BT, Chun CM, Fullwood MJ, Chng WJ, Osato M, Pulikkan JA, Yang H, Chen L, Tenen DG. Core-binding factor fusion downregulation of ADAR2 RNA editing contributes to AML leukemogenesis. Blood 141(25):3078-3090, 2023. e-Pub 2023. PMID: 36796022.
- Alagha, R, Chan, WL, Edwin, TS, Lee, J, Jen, WY, Lip, CK, Smitasin, N, Somani, J. The Mote in Thy Brother's Eyes - Fusarium Solani in Leukemia Host. Infectious Diseases in Clinical Practice 31(2), 2023. e-Pub 2023.
- Ong SY, Si Yun MT, Abdul Halim NA, Christopher D, Jen WY, Gallardo C, Hwee Yim AT, Woon YK, Ng HJ, Ooi M, Wong GC. Real-World Experience of Measurable Residual Disease Response and Prognosis in Acute Myeloid Leukemia Treated with Venetoclax and Azacitidine. Cancers (Basel) 14(15):3576, 2022. e-Pub 2022. PMID: 35892834.
- Ko SQ, Hooi BMY, Koo C, Chor DWP, Ling ZJ, Chee YL, Jen WY. Remote monitoring of marginalised populations affected by COVID-19: a retrospective review. BMJ Open 10(12):e042647, 2020. e-Pub 2020. PMID: 33384398.
- Jen WY, Kristanto W, Teo L, Phua J, Yip HS, MacLaren G, Teoh K, Sim TB, Loh J, Ong CC, Chee YL, Kojodjojo P. Assessing the impact of a Pulmonary Embolism Response Team and treatment protocol on patients presenting with acute pulmonary embolism. Heart Lung Circ 29(3):2345-353, 2020. e-Pub 2020. PMID: 30910512.
- Jen WY, Yoong J, Liu X, Tan MSY, Chng WJ, Chee YL. Qualitative study of factors affecting patient, caregiver and physician preferences for treatment of myeloma and indolent lymphoma. Patient Prefer Adherence 17(14):301-308, 2020. e-Pub 2020. PMID: 32109996.
- Ng CH, Jen WY, Koh LP, Ooi M, CHAN E, ZHOU J, CHNG WJ. A phase 1 study on midostaurin plus panobinostat in unfit acute myeloid leukaemia and high-risk myelodysplastic syndrome. Clin Investig (Lond) 10(2):28-34, 2020. e-Pub 2020.
- Winata AS, Jen WY, Teng ML, Hing W, Iyer SG, Ma V, Chua H. Intravenous maintenance fluid tonicity and hyponatraemia after major surgery – a cohort study. Int J Surg 67:1-7, 2019. e-Pub 2019. PMID: 31075533.
- Jen WY, Jeon YS, Kojodjojo P, Er Lee EH, Lee YH, Ren YP, Shawn Tan TJ, Song Y, Zhang T, Teo L, Feng M. A New Model for Risk Stratification of Patients With Acute Pulmonary Embolism. Clin Appl Thromb Hemost 24:277S-284S, 2018. e-Pub 2018. PMID: 30370786.
Other Articles
- Jen WY, Kantarjian H, Kadia TM, DiNardo CD, Issa GC, Short NJ, Yilmaz M, Borthakur G, Ravandi F, Daver NG Combination therapy with novel agents for acute myeloid leukaemia: Insights into treatment of a heterogenous disease. Br J Haematol. PMID: 38724457.
- Jen WY, Konopleva M, Pemmaraju N Tagraxofusp, a first-in-class CD123-targeted agent: Five-year postapproval comprehensive review of the literature. Cancer. PMID: 38620053.
- Jen WY, Jabbour E, Kantarjian HM, Short NJ SOHO State of the Art Updates and Next Questions | Novel Agents and the Diminishing Role of Allogeneic Stem Cell Transplant in B-Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. PMID: 38538495.
- Thong EWS, Tan SS, Sethi SK, Chee YL, Jen WY Falsely elevated serum vitamin B12 levels in a case of pernicious anemia. Ann Hematol 101(4):889-892, 2022. PMID: 34505941.
- Yu Ng AP, Chee YL, Wong SBJ, Jen WY Methicillin-resistant Staphylococcus aureus (MRSA) panniculitis in a patient undergoing stem cell mobilization. BMJ Case Rep 14(2):e236382, 2021. PMID: 33563686.
- Sia CS, Jen WY, Poon MLM Acquired antibody-mediated pure red cell aplasia following treatment with darbepoetin. Ann Acad Med Singap 49(1):46-48, 2020. PMID: 32200397.
- Jen WY, Chee Y, Khor LK, Nga ME, Poon L, de Mel S Diffuse intrasinusoidal hepatic metastases from occult breast carcinoma presenting as thrombotic microangiopathy: a case report and literature review. J Hematol 4(4):238-241, 2015.
Editorials
- National University Cancer Institute of Singapore (NCIS) Workflow Team. A segregated-team model to maintain cancer care during the COVID-19 outbreak at an academic center in Singapore. Ann Oncol 31(7):840-843, 2020. PMID: 32243893.
Letters to the Editor
- Jen, WY, Jabbour, EJ, Short, NJ, Issa, GC, Haddad, FG, Jain, N, Pemmaraju, N, Daver, N, Masarova, L, Borthakur, G, Chien, KS, Garris, R, Kantarjian, H. A phase 2 trial of mini-hyper-CVD, blinatumomab, and ponatinib in Philadelphia positive acute lymphoblastic leukemia. American journal of hematology 99: 2229-2232, 2024.
- Olesinski EA, Bhatia KS, Mahesh AN, Rosli S, Mohamed JS, Jen WY, Jain N, Garcia JS, Wong GC, Ooi M, Letai A, Konopleva M, Bhatt S. BH3 profiling identifies BCL-2 dependence in adult patients with early T-cell progenitor acute lymphoblastic leukemia. Blood Adv 7: 2917-2923, 2023.
- Cheong MA, Chee Y, Ng HJ, Jen WY. Keeping the bloodline of haematology medical education flowing during a pandemic. Int J Lab Hematol 42: e196-e198, 2020.
Grant & Contract Support
| Date: | 2024 - Present |
| Title: | HealthCARES: Perceptions of Healthcare Financing for Cancer – Awareness, Readiness, Expectations and Support |
| Funding Source: | National University Cancer Institute, Singapore |
| Role: | PI |
| Date: | 2022 - Present |
| Title: | Dissecting and overcoming drug resistance in leukaemia using functional and genomic approaches |
| Funding Source: | National Research Foundation, Singapore |
| Role: | Co-I |
| Date: | 2021 - 2022 |
| Title: | Guiding venetoclax-based combination therapy in AML with BH3 profiling |
| Funding Source: | National University Cancer Institute, Singapore |
| Role: | Co-I |
| Date: | 2021 - Present |
| Title: | Targeted Therapy for Blood Cancer II (Tetrad II) |
| Funding Source: | National Medical Research Council, Ministry of Health, Singapore |
| Role: | Co-PI |
| ID: | CG21Apr2002 |
| Date: | 2020 - 2020 |
| Title: | Telehealth Augmentation of Dorm Ops in COVID-19 |
| Funding Source: | Temasek Foundation, Singapore |
| Role: | PI |
| Date: | 2018 - 2021 |
| Title: | Factors affecting patient, caregiver and physician preferences for treatment of myeloma and indolent lymphoma |
| Funding Source: | National Medical Research Council, Ministry of Health, Singapore |
| Role: | PI |
| ID: | HNIG17Nov002 |
| Date: | 2017 - 2018 |
| Title: | Detection of cell-free DNA in the cerebrospinal fluid of patients with diffuse large B cell lymphoma at risk of central nervous system relapse |
| Funding Source: | National University Cancer Institute, Singapore |
| Role: | PI |
Patient Reviews
CV information above last modified March 19, 2025